BioNxt Begins Lab-Scale ODF Development After Receiving Semaglutide API
BioNxt Solutions has received the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of its oral dissolvable film (ODF) delivery system.
BioNxt Solutions | 03/09/2025 | By Dineshwori | 219
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy